471 related articles for article (PubMed ID: 31615807)
41. The Killing of Human Neuroblastoma Cells by the Small Molecule JQ1 Occurs in a p53-Dependent Manner.
Mazar J; Gordon C; Naga V; Westmoreland TJ
Anticancer Agents Med Chem; 2020; 20(13):1613-1625. PubMed ID: 32329693
[TBL] [Abstract][Full Text] [Related]
42. Inhibition of mir-21, which is up-regulated during MYCN knockdown-mediated differentiation, does not prevent differentiation of neuroblastoma cells.
Buechner J; Henriksen JR; Haug BH; Tømte E; Flaegstad T; Einvik C
Differentiation; 2011 Jan; 81(1):25-34. PubMed ID: 20980091
[TBL] [Abstract][Full Text] [Related]
43. SGO1 is involved in the DNA damage response in MYCN-amplified neuroblastoma cells.
Murakami-Tonami Y; Ikeda H; Yamagishi R; Inayoshi M; Inagaki S; Kishida S; Komata Y; Jan Koster ; Takeuchi I; Kondo Y; Maeda T; Sekido Y; Murakami H; Kadomatsu K
Sci Rep; 2016 Aug; 6():31615. PubMed ID: 27539729
[TBL] [Abstract][Full Text] [Related]
44. Transcription factor activating protein 4 is synthetically lethal and a master regulator of MYCN-amplified neuroblastoma.
Boboila S; Lopez G; Yu J; Banerjee D; Kadenhe-Chiweshe A; Connolly EP; Kandel JJ; Rajbhandari P; Silva JM; Califano A; Yamashiro DJ
Oncogene; 2018 Oct; 37(40):5451-5465. PubMed ID: 29880876
[TBL] [Abstract][Full Text] [Related]
45. Vasoactive intestinal peptide decreases MYCN expression and synergizes with retinoic acid in a human MYCN-amplified neuroblastoma cell line.
Chevrier L; Meunier AC; Cochaud S; Muller JM; Chadéneau C
Int J Oncol; 2008 Nov; 33(5):1081-9. PubMed ID: 18949372
[TBL] [Abstract][Full Text] [Related]
46. Downregulation of c-Myc is involved in TLR3-mediated tumor death of neuroblastoma xenografts.
Lin LL; Huang CC; Wu CL; Wu MT; Hsu WM; Chuang JH
Lab Invest; 2016 Jul; 96(7):719-30. PubMed ID: 27183205
[TBL] [Abstract][Full Text] [Related]
47. [Effects of miR-144 on proliferation, apoptosis and cisplatin resistance by targeting MYCN in pediatric neuroblastoma].
Liu HJ; Li GL; Lei PC
Zhonghua Zhong Liu Za Zhi; 2019 Jul; 41(7):516-521. PubMed ID: 31357838
[No Abstract] [Full Text] [Related]
48. MYCN amplified neuroblastoma requires the mRNA translation regulator eEF2 kinase to adapt to nutrient deprivation.
Delaidelli A; Negri GL; Jan A; Jansonius B; El-Naggar A; Lim JKM; Khan D; Oo HZ; Carnie CJ; Remke M; Maris JM; Leprivier G; Sorensen PH
Cell Death Differ; 2017 Sep; 24(9):1564-1576. PubMed ID: 28574509
[TBL] [Abstract][Full Text] [Related]
49. The long non-coding RNA MYCNOS-01 regulates MYCN protein levels and affects growth of MYCN-amplified rhabdomyosarcoma and neuroblastoma cells.
O'Brien EM; Selfe JL; Martins AS; Walters ZS; Shipley JM
BMC Cancer; 2018 Feb; 18(1):217. PubMed ID: 29466962
[TBL] [Abstract][Full Text] [Related]
50. MYCN-induced E2F5 promotes neuroblastoma cell proliferation through regulating cell cycle progression.
Liu Y; Liu D; Wan W
Biochem Biophys Res Commun; 2019 Mar; 511(1):35-40. PubMed ID: 30765227
[TBL] [Abstract][Full Text] [Related]
51. MYCN is amplified during S phase, and c‑myb is involved in controlling MYCN expression and amplification in MYCN‑amplified neuroblastoma cell lines.
Aygun N; Altungoz O
Mol Med Rep; 2019 Jan; 19(1):345-361. PubMed ID: 30483774
[TBL] [Abstract][Full Text] [Related]
52. Effects of novel pyrrolomycin MP1 in MYCN amplified chemoresistant neuroblastoma cell lines alone and combined with temsirolimus.
McGuire TR; Coulter DW; Bai D; Sughroue JA; Li J; Yang Z; Qiao Z; Liu Y; Murry DJ; Chhonker YS; McIntyre EM; Alexander G; Sharp JG; Li R
BMC Cancer; 2019 Aug; 19(1):837. PubMed ID: 31455317
[TBL] [Abstract][Full Text] [Related]
53. MYCN concurrence with SAHA-induced cell death in human neuroblastoma cells.
Cortés C; Kozma SC; Tauler A; Ambrosio S
Cell Oncol (Dordr); 2015 Oct; 38(5):341-52. PubMed ID: 26306783
[TBL] [Abstract][Full Text] [Related]
54. Down-regulation of MYCN protein by CX-5461 leads to neuroblastoma tumor growth suppression.
Taylor JS; Zeki J; Ornell K; Coburn J; Shimada H; Ikegaki N; Chiu B
J Pediatr Surg; 2019 Jun; 54(6):1192-1197. PubMed ID: 30879743
[TBL] [Abstract][Full Text] [Related]
55. Association of heterogeneous MYCN amplification with clinical features, biological characteristics and outcomes in neuroblastoma: A report from the Children's Oncology Group.
Campbell K; Naranjo A; Hibbitts E; Gastier-Foster JM; Bagatell R; Irwin MS; Shimada H; Hogarty M; Park JR; DuBois SG
Eur J Cancer; 2020 Jul; 133():112-119. PubMed ID: 32492633
[TBL] [Abstract][Full Text] [Related]
56. MicroRNA-497 increases apoptosis in MYCN amplified neuroblastoma cells by targeting the key cell cycle regulator WEE1.
Creevey L; Ryan J; Harvey H; Bray IM; Meehan M; Khan AR; Stallings RL
Mol Cancer; 2013 Mar; 12():23. PubMed ID: 23531080
[TBL] [Abstract][Full Text] [Related]
57. Human neuroblastoma cells with MYCN amplification are selectively resistant to oxidative stress by transcriptionally up-regulating glutamate cysteine ligase.
Veas-Perez de Tudela M; Delgado-Esteban M; Cuende J; Bolaños JP; Almeida A
J Neurochem; 2010 May; 113(4):819-25. PubMed ID: 20180881
[TBL] [Abstract][Full Text] [Related]
58. Clinically Relevant Cytotoxic Immune Cell Signatures and Clonal Expansion of T-Cell Receptors in High-Risk
Wei JS; Kuznetsov IB; Zhang S; Song YK; Asgharzadeh S; Sindiri S; Wen X; Patidar R; Najaraj S; Walton A; Auvil JMG; Gerhard DS; Yuksel A; Catchpoole D; Hewitt SM; Sondel PM; Seeger R; Maris JM; Khan J
Clin Cancer Res; 2018 Nov; 24(22):5673-5684. PubMed ID: 29784674
[No Abstract] [Full Text] [Related]
59. Targeting of the MYCN protein with small molecule c-MYC inhibitors.
Müller I; Larsson K; Frenzel A; Oliynyk G; Zirath H; Prochownik EV; Westwood NJ; Henriksson MA
PLoS One; 2014; 9(5):e97285. PubMed ID: 24859015
[TBL] [Abstract][Full Text] [Related]
60. Detection of MYCN Amplification in Serum DNA Using Conventional Polymerase Chain Reaction.
Ma Y; Lee JW; Park SJ; Yi ES; Choi YB; Yoo KH; Sung KW; Koo HH
J Korean Med Sci; 2016 Sep; 31(9):1392-6. PubMed ID: 27510381
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]